Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
NOVA1 encodes a neuron-specific RNA-binding protein, a member of the Nova family of paraneoplastic disease antigens, that is recognized and inhibited by paraneoplastic antibodies. Additionally we are shipping NOVA1 Proteins (10) and many more products for this protein.
Showing 10 out of 75 products:
Human Monoclonal NOVA1 Primary Antibody for WB - ABIN393361
Alkelai, Greenbaum, Rigbi, Kanyas, Lerer: Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. in Psychopharmacology 2009
Show all 5 references for 393361
Human Monoclonal NOVA1 Primary Antibody for WB - ABIN393331
Vasan, Glazer, Felix, Lieb, Wild, Felix, Watzinger, Larson, Smith, Dehghan, Grosshennig, Schillert, Teumer, Schmidt, Kathiresan, Lumley, Aulchenko, König, Zeller, Homuth, Struchalin, Aragam, Bis, Rivadeneira, Erdmann, Schnabel, Dörr, Zweiker, Lind, Rodehe: Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. in JAMA : the journal of the American Medical Association 2009
Show all 5 references for 393331
Human Polyclonal NOVA1 Primary Antibody for ICC, IF - ABIN4340455
Li, Sun, Wang, Gao, Liu, Gao, Li, Zhang: Dynamic expression pattern of neuro-oncological ventral antigen 1 (Nova1) in the rat brain after focal cerebral ischemia/reperfusion insults. in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2012
Human Polyclonal NOVA1 Primary Antibody for ELISA, WB - ABIN562029
Jelen, Ule, Zivin: Cholinergic regulation of striatal Nova mRNAs. in Neuroscience 2010
Cow (Bovine) Polyclonal NOVA1 Primary Antibody for WB - ABIN2778798
Ratti, Fallini, Colombrita, Pascale, Laforenza, Quattrone, Silani: Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV. in The Journal of biological chemistry 2008
Human Polyclonal NOVA1 Primary Antibody for IHC (p), IHC - ABIN314323
Jelen, Ule, Zivin, Darnell: Evolution of Nova-dependent splicing regulation in the brain. in PLoS genetics 2007
NOVA1 suppression was frequently noted in the gastric cancer microenvironment, and attenuated NOVA1 expression in tumor cells was associated with tumor progression and poor prognosis.
Nova1 interacts with GABAARgamma2 not only in the central nervous system but also in hepatocellular carcinoma. Nova1's potential mechanism as an oncogene (show RAB1A Antibodies) may due to its interaction with GABAA (show GABRg1 Antibodies) Rgamma2.
Loss of NOVA1 is associated with gastric cancer.
Quantitative proteomic analysis was performed to help elucidate a molecular distinction between glioblastoma and oligodendroglioma; analysis showed HSPB1 (show HSPB1 Antibodies) and NOVA1 to be discriminating factors.
Data indicate RNA binding protein (show PTBP1 Antibodies) NOVA1 as a target of microRNA miR (show MLXIP Antibodies)-339.
MiR (show MLXIP Antibodies)-181b-5p is a tumor suppressor in astrocytoma that inhibits tumor progression by targeting NOVA1.
High expression of NOVA1 correlates with poor prognosis in hepatocellular carcinoma.
a regulation of LEDGF (show PSIP1 Antibodies) interaction with chromatin by cellular partners of its PWWP domain could be involved in several processes linked to LEDGF (show PSIP1 Antibodies) tethering properties, such as lentiviral integration, DNA repair or transcriptional regulation
Gene silencing and overexpression of the nELAV member HuD (show ELAVL4 Antibodies) in motoneuronal NSC34 cells indicate that Nova1 mRNA stability and translation are positively and strongly controlled by the nELAV proteins
Semiquantitative estimation of circulating anti-Ri antibodies demonstrated a renewed increase in antibody levels preceding relapse of the cancer, as confirmed using F-fluorodeoxyglucose positron emission tomography (FDG (show SMUG1 Antibodies)-PET)
RBM4a (show RBM4 Antibodies) ablation enhanced the relative level of exon 4-excluded neuro-oncological ventral antigen 1 (Nova1(-4)) transcripts, which were predominantly generated in embryonic BAs
identify Nova-1 and hnRNP M (show HNRNPM Antibodies) as D2R (show DRD2 Antibodies) pre-mRNA-binding proteins and show their antagonistic role in the alternative splicing of D2R (show DRD2 Antibodies) pre-mRNA.
integrative network revealed combinatorial regulation by Nova (show HNRNPK Antibodies) and the neuronal splicing factor (show SLU7 Antibodies) Fox, interplay between phosphorylation and splicing, and potential links to neurologic disease
Nova (show HNRNPK Antibodies) regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer
CLIP (cross-linking and immunoprecipitation) reveals Nova (show HNRNPK Antibodies) coordinately regulates a biologically coherent set of RNAs encoding multiple components of the inhibitory synapse, an observation that may relate to the cause of abnormal motor inhibition in POMA
These studies demonstrate that in addition to its previously described role as a splicing activator, Nova-1 autoregulates its own expression by acting as a splicing repressor.
Assays of splicing intermediates of Nova (show HNRNPK Antibodies)-regulated transcripts in mouse brain revealed that Nova (show HNRNPK Antibodies) preferentially regulates removal of introns harbouring (or closest to) YCAY clusters
Nova1/Nova2 (show NOVA2 Antibodies) double knockout mice are paralyzed and fail to cluster AChRs at the neuromuscular junction, and breeding them with transgenic mice constitutively expressing Z(+) agrin (show AGRN Antibodies) in motor neurons rescued AChR clustering
This gene encodes a neuron-specific RNA-binding protein, a member of the Nova family of paraneoplastic disease antigens, that is recognized and inhibited by paraneoplastic antibodies. These antibodies are found in the sera of patients with paraneoplastic opsoclonus-ataxia, breast cancer, and small cell lung cancer. Alternatively spliced transcripts encoding distinct isoforms have been described.
neuro-oncological ventral antigen 1
, lipid A export ATP-binding/permease protein
, RNA-binding protein Nova-1
, onconeural ventral antigen 1
, paraneoplastic Ri antigen
, ventral neuron-specific protein 1